Highlights

  • Enlitic completed a A$15 million placement and ten-for-one capital consolidation during the quarter, with convertible notes converted into CDIs leaving the company debt-free.
  • Ensight version 2.3, released 6 October 2026, expands the platform from 8 to 12 commercial applications and adds Sectra — which handles 170 million imaging examinations annually — as a second major integration.
  • Annual recurring revenue from Ensight stood at approximately US$760,000, with a further US$360,000 of contracted pipeline waiting to go live across the US, New Zealand and Australia.
  • The company signed 10 new customer agreements worth approximately US$1.0 million in total contract value, led by a US$806,000 University of Michigan Health migration deal.

A fresh capital base, no debt and a bigger product — Enlitic (ASX:ENL) used its September quarter to clear its balance sheet and broaden the reach of its Ensight imaging data platform. Convertible notes are gone, converted into CDIs alongside a A$15 million placement that closed during the period, and the platform itself has taken a significant step with the addition of Sectra as its second major integration. For a company selling into hospital radiology systems, the breadth of integration partnerships is as important as any single contract, because healthcare institutions rarely replace their core imaging infrastructure without already-integrated software.

Placement and Balance Sheet

The A$15 million placement was completed during the September quarter and was accompanied by a ten-for-one capital consolidation and a non-underwritten security purchase plan that raised approximately A$739,000. All outstanding convertible notes — which had previously added interest expense and conversion risk to the company's balance sheet — were converted into CDIs as part of the same process. The result is a company with no external debt and a balance sheet that is simpler and more transparent for prospective customers and partners evaluating Enlitic's financial stability.

Cash receipts from customers were US$551,000, down from US$2.3 million in the June quarter. The report explains that receipts and revenue are different measures because recognition timing differs from cash collection, and that the movement does not represent a revenue decline of that magnitude. Operating expenditure was US$3.015 million for the quarter, comparable to US$3.042 million in the prior period. Financing activities brought in US$9.822 million net, reflecting equity proceeds of US$11.054 million less US$1.237 million of transaction costs. Closing cash was US$9.453 million, and the company says the placement proceeds are expected to fund operations through to cash flow break-even.

Ensight ARR and New Contracts

Annual recurring revenue from the Ensight platform stood at approximately US$760,000 at quarter-end, with US$360,000 of additional contracted pipeline awaiting go-live across the US, New Zealand and Australia. Three go-lives have been completed since May 2026 through the Intelerad integration at sites in New Zealand, Colorado and Iowa, establishing a track record that supports sales to other Intelerad customers.

The company signed 10 new customer agreements with total contract value of approximately US$1.0 million. The largest was a US$806,000 agreement with University of Michigan Health – Sparrow, covering data standardisation and Ensight deployment across approximately 10.6 million imaging studies, expected to complete within 12 months. Contract value is recognised as revenue as work is delivered, not at signing. Rolling 12-month contract value fell to approximately US$8.34 million from US$9.39 million, which the company attributes to smaller contracts signed in the past two quarters. It expects lumpy contract timing to persist given the scale of large migration projects.

Ensight 2.3 and Sectra

Ensight version 2.3, released on 6 October 2026, grows the platform from 8 to 12 commercial applications and introduces Sectra as a second major PACS integration alongside Intelerad. Sectra systems manage more than 170 million imaging examinations a year globally, meaning the integration gives Enlitic access to a substantial portion of the world's radiology workflow. A third integration is included in version 2.3 but remains subject to customer validation testing, with further details expected before the end of 2026. Management priorities include securing larger enterprise contracts, accelerating Ensight adoption across the Intelerad and Sectra installed bases, and delivering existing migration projects on schedule. No numerical revenue or contract guidance was provided.